Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline/Bristol-Myers

Executive Summary

IND for H2 receptor-antagonist BMY 25368, under development by SmithKline, transferred back to Bristol-Myers. The potential "son of Tagamet" was a part of June 1987 swap that involved the granting of U.S. and Canadian comarketing rights to Bristol for OTC cimetidine. SmithKline says it is discussing "the entire situation" with Bristol-Myers....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel